🔍 New Milestone: Our #AirSCWO technology has demonstrated outstanding effectiveness in destroying pharmaceutical waste for a manufacturer, achieving >99.9% destruction of halogenated solvents and organic wastes, surpassing conventional methods. 💊 Pharmaceutical waste poses environmental and health risks. We believe AirSCWO technology is uniquely positioned to address these wastes without producing harmful byproducts. Unlike traditional methods that can result in secondary pollutants and additional costs, AirSCWO transforms organic waste into harmless byproducts of water and minerals, thereby significantly reducing the impact of this industry on the environment and public health. Stay tuned for more case studies showcasing the versatility and efficacy of AirSCWO for various industries. Read the full release: https://lnkd.in/ghWUhPmh #Cleantech #WasteManagement #Sustainability #Pharmaceuticals #Innovation $SCWO
374Water’s Post
More Relevant Posts
-
Mini series on Hashtag #SciencePolicy – 2/X - B The reference again (could not change the link in the last post) https://lnkd.in/gssVx229
The EU’s Per- and Polyfluoroalkyl Substances (PFAS) Ban: A Case of Policy over Science
mdpi.com
-
Internal Medicine| Neuroscience | Endocrine | Diabetes | Obesity | Medical Physician & healthcare leader with a proven track record of success in driving medical strategy, improving clinical outcomes and quality of care,
The benefit of GLP-1RA semaglutide in preventing the progression of renal events in the FLOW trial. DSMB stops the trial early for efficacy! https://lnkd.in/dB4t3jZx
News Details
novonordisk.com
-
Interesting article
People Are Overdosing on Wegovy, Poison Control Data Shows — Gizmodo
apple.news
-
We have just updated our page. Stay tuned for more upcoming news!
Bioecopest | LinkedIn
it.linkedin.com
-
An upcoming webinar from Milestone Inc. will dive into SRC technology and compare it to rotor-based technologies before demonstrating the advantages and benefits of SRC digestion as it is used in several application areas. Register here: https://lnkd.in/eHHzc3zr
-
-
Top Voice - Marketing Automation |Helping Businesses Elevate CX with Strategic Tech Alliances & SaaS Solutions | Driving Strategic Partnerships WhatsApp TSP program🚀🌐 Available for Consulting and Full-Time Roles
ℹ️ Considering SMS compression for efficient messaging? Explore its benefits like reduced data usage and faster transmission. However, be aware of potential drawbacks such as message fidelity loss and compatibility issues. Alternatives like MMS, instant messaging, and email offer diverse options based on content and recipient preferences. When choosing the best form of mobile communication, assess factors like message content and network capabilities. Stay updated on industry trends and gather user feedback for continuous optimization. Let's ensure effective mobile communication together! #SMSCompression #Efficiency #Alternatives #Optimization #karix #Tanla #catchkhan 📱💬 If you find these insights helpful, show your support by liking and sharing with your network! Let's stay informed and connected in the world of mobile communication. 🌐🚀 https://lnkd.in/gTtb-sWe
- Link-in-bio
bit.ly
-
If you're worried about the potential impact of GLP-1 medications on your business, you should join this Foresight Co-Lab. This multi-client research project will help you gain clarity about the future of anti-obesity medication and how these drugs could impact brands and businesses well beyond the health sector. Learn more about this exciting Foresight Co-Lab opportunity: https://lnkd.in/dYmzA6es
Beyond Ozempic
kantar-inspiration.com
-
Internal Communications | Branding | Employee Events | Change Management | Employer Branding | Engagement | Culture | Recognition | Mergers & Acquisitions
The Pharma R&D Annual Review 2024 is out now! For over 30 years, Citeline tracked how the climate shifts, revealing the currents and tides shaping the drug development landscape. Download the full report below!
Citeline on LinkedIn: #pharmarnd #annualreview #pharmatrends
linkedin.com
-
It is amazing to see the commercial appeal of Novo's "weight loss" (+heart issues) drugs. Novo Nordisk increased revenue and profit guidance once again 😮 . The optimism around the share price consolidates the company as the largest market cap in Europe (>$450bn). Consensus still has a c.10% upward adjustment to make to revenues to catch up with the new guidance for the year (c.35% vs c.30% previously). At 20-25x 2025 earnings the company does not screen as rich, looking at historical levels and, considering the demographic trends, Novo is likely to be a perma-winner. Let's now wait for the full 9M23 numbers on 2-Nov. #novo #novonordisk #pharma #diabetes #obesity #ozempic #wegovy https://lnkd.in/ehqJJq8f
News Details
novonordisk.com
